HIV INFECTIONS

This study tested a new two-step vaccine approach to protect HIV-infected adults from pneumococcal infections, a common cause of serious illness in this group. The standard vaccine often doesn't work well in people with lower immune cell counts. The study involved 212 participant…

This study tested a vaccine called Triplex® in 94 adults who have both HIV and cytomegalovirus (CMV). The goal was to see if the vaccine is safe and helps the immune system control CMV. Participants received two shots of the vaccine or a placebo over 4 weeks and were followed for…

This study tested an experimental HIV vaccine in 132 healthy, HIV-negative adults. The vaccine uses a harmless virus (ALVAC) to deliver HIV proteins, plus a protein boost (gp120) with an adjuvant to strengthen the immune response. The main goals were to check safety and measure w…

This study tested an experimental HIV vaccine in 117 healthy, HIV-negative adults to see if it is safe and triggers an immune response. Participants received several injections of the vaccine or a placebo. The main goals were to check for side effects and measure antibody levels.…

This large study tested Moderna's COVID-19 mRNA vaccine in over 14,000 people living with HIV or other conditions that increase the risk of severe COVID-19. The goal was to see how well different vaccine doses prevent COVID-19. Participants received either the original or an upda…

This early-stage study tested a new HIV vaccine in 51 healthy adults to see if it is safe and triggers an immune response. The vaccine aims to train the body to produce special antibodies that can fight HIV. Researchers also tested different combinations of adjuvants (ingredients…

This study tested two different schedules of an experimental HIV vaccine in 147 healthy adults to see which one triggers a stronger immune response. Volunteers received either three DNA shots followed by one booster, or two DNA shots followed by two boosters. The goal was to find…

This study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause s…

This early-stage trial tested an experimental HIV vaccine in 38 healthy infants born to HIV-positive mothers. The vaccine was designed to teach the immune system to recognize HIV. The main goal was to see if it was safe and whether it triggered an immune response. The study is co…

This early-stage trial tested an experimental HIV vaccine called Trimer 4571 in 32 adults with HIV who were already on effective antiretroviral therapy (ART). The main goal was to check if the vaccine is safe and tolerable, and to see if it helps the immune system produce broadly…

This early-stage trial tested two experimental HIV vaccines in 34 healthy, HIV-negative adults. The goal was to see if the vaccines were safe and whether they triggered an immune response. The vaccines use a harmless chimpanzee virus to deliver HIV proteins, followed by a booster…

This Phase 1 trial tested a DNA vaccine designed to teach the immune system to recognize HIV. 46 healthy adults received the vaccine with or without a protein boost. The main goal was to see if it is safe and whether it triggers the right immune cells. Results will help decide if…

This early-stage trial tested a new HIV vaccine in 24 healthy, HIV-negative adults. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus to the immune system. The main goal was to check if the vaccine is safe and whether it triggers an immune respon…

This Phase 1 trial tested an experimental HIV vaccine in 127 healthy, HIV-uninfected adults. The vaccine uses a protein called BG505 SOSIP.664 gp140 combined with various adjuvants to boost immune response. The main goal was to check safety and how well the vaccine triggers an im…

This study tested two ways to offer HIV treatment, hepatitis C treatment, and substance use disorder medications to people who inject drugs. One group received a telehealth-enhanced program with on-demand services like mobile blood draws and counseling, while the other group got …

This study tests a new way to help vulnerable people with HIV get diagnosed and start treatment right away using a mobile screening unit. Participants receive the once-daily pill Biktarvy on the same day they are enrolled. The goal is to see if this approach helps them stay in ca…

This study tested the drug delamanid in 37 children with multidrug-resistant tuberculosis (MDR-TB), some of whom also had HIV. The goal was to see how the drug works in the body, check for side effects, and find the right dose. Children took delamanid along with their regular TB …

This study tests a combination of three HIV drugs (amprenavir, lopinavir, and ritonavir) in patients whose current treatments are no longer working. The goal is to see if this new mix can lower the amount of HIV in the blood over 26 weeks. Participants are HIV-positive adults who…

This study tested a once-daily combination of three HIV drugs (FTC, ddI, efavirenz) in 39 adults who had never taken HIV medication before. The goal was to see if this simpler, once-a-day pill routine worked well and had fewer side effects than older treatments. Participants had …

This trial compares a once-daily combination of three HIV drugs (emtricitabine, didanosine, and efavirenz) to the standard multi-pill regimen containing a protease inhibitor. The goal is to see if the simpler daily pill works just as well at keeping the virus undetectable, while …

This study tested whether a mobile health unit that offers HIV prevention, treatment, and medication for opioid use disorder all in one place helps people who inject drugs stay on treatment. About 447 adults with opioid use disorder took part. The goal was to see if this approach…

This study gave HIV-1 patients continued access to the drug etravirine until they could switch to a local treatment. It included 180 people aged 2 and older who had already benefited from the drug in a previous trial. The main goal was to monitor safety while providing the medica…

This study tested whether personalized text message reminders can help young people with HIV take their medication consistently. 210 participants from 12 clinics received either standard care or tailored text reminders for 6 months. The goal was to see if the texts improved medic…

This study tested whether starting HIV treatment on the same day and providing care in community centers for people who inject drugs improves viral suppression. 800 participants were randomly assigned to same-day or standard treatment start, and to community or government-based c…

This study tested a stepped-care program where trained non-specialists provided mental health support and HIV medication adherence help to 280 people in rural Zimbabwe. Participants had both depression and high HIV viral loads. The goal was to see if this approach could improve v…

This Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface an…

This study looked at two ways to control HIV in 171 adults who had never been treated before. Everyone started with a daily pill (dolutegravir/lamivudine). Once the virus was undetectable, participants could choose to switch to a shot (cabotegravir plus rilpivirine) given every t…

This study tested a mobile phone-based wellness program (WISH) to help veterans with HIV quit smoking. 234 participants were split into two groups: one received the WISH program, the other got standard care (quitline and text support). The goal was to see if the wellness program …

This study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became …

This study looked at whether adults aged 50 and older living with HIV could safely switch from a three-drug pill to a simpler two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch and were f…

This early-stage study tested a single injection of a new drug, lipovirtide, in 46 HIV-positive adults who had never taken antiviral medication. The main goal was to check if the drug is safe and how the body processes it. This is a first step toward finding new treatments to con…

This early-stage trial tested multiple doses of an injectable drug called lipovirtide in 24 adults with HIV who had never taken antiretroviral therapy. The main goal was to check safety and how the drug moves through the body, with a secondary look at whether it can lower HIV lev…

This study tested a new way to manage high blood pressure and heart disease risk in people living with HIV in Botswana. Over 4,600 adults on HIV treatment took part. The goal was to see if adding heart health checks and treatment to regular HIV clinic visits helps more people con…

This study looked at HIV-positive adults who switched from a standard three-drug therapy to either a two-drug or a three-drug regimen. Researchers wanted to see if the two-drug option could reduce long-term side effects while keeping the virus under control. The main focus was on…

This study tested a counseling program for couples in Zambia to help pregnant women living with HIV stay healthy. Nearly 500 couples took part. The program aimed to improve HIV medication adherence and viral suppression through relationship strengthening.

This study tested a special digital pill and smartphone app to help HIV-negative men who have sex with men and who also have substance use disorder take their daily HIV prevention medication (PrEP) consistently. Forty participants took a PrEP pill with a sensor that recorded when…

This study tested whether special cookies made from Golden Rice and an herb called Piper crocatum could lower fasting blood sugar and improve quality of life in 102 people living with HIV who also have high blood sugar. Participants ate either the Golden Rice cookies or plain con…

This study tested whether people with well-controlled HIV can safely take their antiretroviral drugs only 4 days in a row each week, instead of every day. Over 600 adults with stable HIV participated. The main goal was to see if the 4-day schedule kept the virus suppressed just a…

This study tested whether adding Interleukin-2 (IL-2) to standard HIV drugs could increase CD4 immune cells in patients whose current treatment was failing and who had very low CD4 counts (≤200). Fifty-seven adults with HIV-1 took part. The main goal was to see if their CD4 count…

This study tested a once-daily combination of three HIV drugs (tenofovir, emtricitabine, and efavirenz) in 70 adults with both HIV and tuberculosis. Participants had not taken HIV medication before and had been on TB treatment for less than three months. The goal was to see if th…

This study tested two versions of the H1N1 flu vaccine in 306 people living with HIV. One vaccine included an adjuvant (a booster ingredient) and the other did not. The goal was to see which vaccine was safer and better at protecting against the flu. Participants were followed fo…

This study tested whether adding the drug maraviroc to standard HIV treatment could help improve immune function in people whose CD4 counts remain low even when the virus is well-controlled. It involved 60 HIV-positive adults with low CD4 counts and little recent immune improveme…

This study tested whether HIV patients with long-term viral suppression could switch to a single boosted drug (darunavir/r) instead of staying on a standard combination of drugs. 225 adults with well-controlled HIV took part. The goal was to see if the single-drug approach could …

This study tested whether adding an extra HIV drug (enfuvirtide) to standard treatment for 6 months helps people with very low CD4 counts recover their immune system faster. It included 195 adults newly diagnosed with HIV who had a high risk of getting AIDS. The goal was to see i…

This study looked at whether people with HIV who have their virus under control can switch from the injectable drug enfuvirtide to the oral pill raltegravir. 170 participants were randomly assigned to either stay on their current treatment or switch to raltegravir. The goal was t…

This study looked at 35 people with HIV who had never taken HIV drugs before. They all received a daily combination of three medications (atazanavir, ritonavir, tenofovir/emtricitabine) in special bottles that recorded every time they opened them. The goal was to measure how much…

This study tested whether people with HIV who have high immune cell counts (CD4 above 500) can safely take antiretroviral drugs in 6-month cycles—6 months on treatment, then 6 months off—instead of taking them every day. The goal was to see if this approach could keep their immun…

This study tested whether adding a powerful HIV drug called FUZEON® to standard antiretroviral therapy could help people with HIV who also have a rare brain infection called PML. PML is caused by a virus that attacks the brain when the immune system is weak. The goal was to see i…

This study tests whether interleukin-2 (IL-2) can help maintain CD4 cell counts in people with HIV who have not yet started antiretroviral therapy. 130 participants with CD4 counts between 300 and 500 will receive IL-2 injections. The goal is to see if IL-2 can delay the need for…

This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV. 140 participants received either alendronate or a placebo, along with calcium and vitamin D, for 2 years. The goal was to see if the drug could strengthen bones and r…

This study tested two different two-drug combinations in 61 HIV patients who had never taken protease inhibitors before. The goal was to see if these combinations could lower the amount of virus in the blood to very low levels (below 50 copies/mL) after 16 weeks. The study also c…

This study tested two statin drugs, rosuvastatin and pravastatin, in 86 people with HIV who also had high cholesterol. The goal was to see which drug lowered LDL (bad) cholesterol better and was safer when taken with HIV medications. Participants took one of the two statins for 4…

This study tested two different drug combinations for people with HIV whose first treatment stopped working. 558 participants received either standard second-line drugs plus a newer integrase inhibitor (raltegravir) or the standard second-line drugs alone. The main goal was to se…

This completed study tested a health system intervention called ENHANCE in 1,837 adults aged 40+ with at least two chronic conditions (HIV, high blood pressure, diabetes, asthma, or depression). The intervention included a clinical decision support tool for clinicians, health edu…

This study tested a data-to-care approach to reconnect people living with HIV in Ukraine who had fallen out of care. Researchers used health records to identify 160 participants and help them re-engage in HIV care, start or restart antiretroviral therapy, and achieve viral suppre…

This study offers continued access to the HIV medication dolutegravir for children and teenagers who previously took part in related studies. About 100 participants who tolerated the drug well and still need it will receive age-appropriate doses every 12 weeks until the drug is l…

This study tested the safety and dosing of long-acting injectable HIV medications (cabotegravir and rilpivirine) in 168 children and adolescents whose HIV was already well-controlled with daily pills. Participants first took oral versions to check tolerance, then switched to shot…

This completed study looked at whether people with HIV can safely donate a kidney to others with HIV. Only 3 participants were enrolled, and the main goal was to track any side effects from the donor surgery. The study also monitored donors for long-term kidney problems and chang…

This study tested whether a drug called alirocumab, which lowers cholesterol, can reduce heart disease risk in people with HIV. The trial involved 118 adults aged 40 and older with well-controlled HIV and high heart disease risk. Participants received either alirocumab or a place…

This study tested the HIV medication Genvoya (a single daily pill) in 129 teenagers and children with HIV. The goal was to check how the drug is processed in the body, confirm the right dose, and see if it is safe. Participants included teens new to HIV treatment and children who…

This study looked at how safe and effective a hepatitis A vaccine is for people with HIV, aged 1 to 50. About 392 participants received two vaccine doses six months apart. Researchers checked their blood for antibodies and tracked any side effects for a month after each dose. The…

This pilot study tested a 'polypill' that combines four heart failure medications into one capsule, aiming to make it easier for patients to stick with their treatment. The trial included 35 adults with heart failure and reduced ejection fraction, some of whom also had HIV. Resea…

This early-stage study tested a new experimental HIV drug called VH4524184 in 84 healthy adults to see if it is safe and how the body processes it. The study also looked at whether the drug affects a key liver enzyme. Because HIV requires lifelong treatment, this is not a cure bu…

This study tested whether trained community health workers visiting pregnant women at home could improve health for both mothers and children in a rural area of South Africa. The program focused on supporting women with HIV, depression, or alcohol use, and on improving child grow…

This study tested two strategies to improve HIV care among people who inject drugs and men who have sex with men in India. One group received care at integrated centers that offer harm reduction, testing, and treatment all in one place. The other group got the same care plus fina…

This early-stage study tested whether an experimental antibody called VRC01 is safe and can lower the amount of HIV in the blood of 24 adults who were recently infected. Some participants received VRC01 alone, while others received it together with standard HIV medications. The m…

This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 adolescents aged 12 to 17 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could control the virus as well as standard three-drug combin…

This study tested three football-based programs for teen girls in Zambia to improve HIV testing, birth control use, and mental health. Over 2,100 girls from 32 schools took part. The programs aimed to make it easier for girls to get sexual health services and stick with HIV treat…

This small early-phase trial tested a personalized vaccine for HIV made from each patient's own immune cells and inactivated virus. Eleven HIV-positive volunteers who had never taken antiretroviral therapy received the vaccine and then temporarily stopped their regular HIV medica…

This early-stage trial tested a therapeutic HIV vaccine made from each patient's own white blood cells. The goal was to see if it is safe and can boost the immune system to better control HIV. Forty adults on stable HIV treatment took part, receiving either a vaccine loaded with …

This completed Phase 2a trial tested two experimental oral drugs, VH4004280 and VH4011499, in 44 adults with HIV who had never taken antiretroviral therapy. The goal was to see how well these capsid inhibitors could lower the amount of virus in the blood over 10 days. The study a…

This study tested a program where Black and Hispanic young adults (ages 18-29) with HIV used video calls to talk with trained peer health coaches. The goal was to help them take their HIV medication regularly and lower the amount of virus in their blood. The program included eigh…

This study looked back at medical records of 800 people with HIV to compare two drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus suppressed over 48 weeks. Participants were adults already on HIV…

This study tested a digital pill and smartphone app to help people with substance use disorders take their HIV prevention medication (PrEP) consistently. Thirty HIV-negative men who have sex with men and have moderate to severe substance use disorder participated. They used a dig…

This study tested a short video shown in HIV clinic waiting rooms to encourage patients to start and stick with their HIV medications, stay in care, and protect their partners. Over 4,000 patients from clinics serving mostly African American and Hispanic communities took part. Th…

This study looked at whether people with HIV who regularly use cannabis could stop for 28 days and whether that would improve their mood, pain, sleep, and HIV viral load. Twenty-five participants were given financial incentives to stay cannabis-free, with urine tests to confirm. …

This study tested three rapid, point-of-care HIV tests to see how well they work compared to standard lab tests. Researchers enrolled 224 adults at high risk for HIV in Baltimore. The goal was to see if faster results help more people start treatment or prevention the same day.

This study tested a rapid fingerstick test that checks for both HIV and syphilis at the same time in pregnant women visiting prenatal clinics in Guatemala. The goal was to see if this quick, on-the-spot screening would lead to more women being diagnosed and treated during pregnan…

This study tested a new rapid HIV test for infants in Zambia that gives results in under an hour, compared to standard lab tests that take weeks. Researchers wanted to see if faster diagnosis would lead to more babies starting treatment sooner. Over 1,600 HIV-exposed infants were…

This study tested a strategy of using rapid, point-of-care diagnostic tests for sexually transmitted infections (STIs) in pregnant women attending antenatal clinics in Zimbabwe. Over 1,000 women were offered testing for chlamydia, gonorrhea, trichomoniasis, syphilis, and hepatiti…

This pilot study tested whether watching a culturally tailored telenovela (soap opera) online could help Latinas in North Carolina adopt HIV prevention behaviors like using condoms, getting tested, and learning about PrEP. 95 women participated, watching four 10-minute episodes o…

This completed trial in South Africa tested four support strategies—case management, food vouchers, peer buddies, and community PrEP pick-up points—to help female sex workers and young women stay on PrEP, a daily pill that prevents HIV. 304 participants were randomly assigned to …

This study looked at how safe and effective a daily HIV prevention pill (TAF-FTC) is in 54 Kenyan cisgender women. Participants took different numbers of doses each week to mimic real-world use. The goal was to measure drug levels in the blood and tissues, helping doctors better …

This study looks at how often cisgender women in Kenya need to take the HIV prevention pill Truvada (TDF-FTC) to keep protective drug levels in their blood. Participants are randomly assigned to take 2, 4, or 7 doses per week for up to 16 weeks, and their drug levels are measured…

This study tested whether taking the tuberculosis prevention drug isoniazid for 36 months instead of the usual 6 months could better prevent TB in adults with HIV. Nearly 2,000 participants in Botswana were randomly assigned to either short or long treatment. The goal was to see …

This study tested whether a peer-driven program could help African American and Hispanic/Latino men who have sex with men start taking PrEP, a daily pill that prevents HIV. 98 men who were not on PrEP joined the program. The goal was to see if talking with trained peers made them…

This study tested whether a mobile app (GeoPassport), financial incentives, and peer mentor support could help men who have sex with men and transgender women leaving jail access HIV prevention services like PrEP and testing. 233 participants were enrolled and followed for 9 mont…

This completed study tested a van-based program in Baltimore that offered drug checking and HIV prevention medication (PrEP) to people who use drugs. Nearly 500 participants were recruited to see if the program helped them start or stay on PrEP and reduce risky behaviors. The goa…

This large study tested an experimental HIV vaccine in over 5,400 healthy South African adults at risk of HIV. The vaccine was designed to teach the immune system to fight HIV. Unfortunately, the vaccine did not prevent HIV infection, and the trial was stopped early. The results …

This study tested a program called Malkia Klabu ("Queen Club") in Tanzania. The program made local drug shops more welcoming for adolescent girls and young women, so they could easily get HIV prevention services and contraception. Researchers looked at whether this approach incre…

This study tested whether a simpler HIV drug combination (lopinavir/ritonavir alone) could safely prevent mothers from passing HIV to their babies during pregnancy, compared to the standard three-drug combo. About 105 pregnant women with well-controlled HIV took part. The goal wa…

This study tested whether training siblings to talk about HIV PrEP helps Latino men who have sex with men start taking it. 288 participants were split into two groups: one where siblings learned to discuss PrEP, and another where siblings discussed vaccines instead. The goal was …

This large study tested whether an injectable drug called cabotegravir, given every two months, could prevent HIV infection as well as or better than daily Truvada pills. It enrolled over 4,500 HIV-negative men and transgender women who have sex with men and are at high risk for …

This study tested a special toolkit designed to help African American women at risk for HIV get access to PrEP (a daily pill that prevents HIV). The toolkit also addresses intimate partner violence, which can make it harder for women to seek prevention. Researchers worked with tw…

This study tested a pop-up clinic inside a van for women who inject drugs and exchange sex in north Seattle. The goal was to see if offering HIV prevention pills, addiction medications, and quick STI testing in a convenient location would help more women start and stay on these t…

This study tested a simple checklist and peer coaching program for people who inject drugs and are hospitalized with serious infections. The goal was to see if these tools could help start HIV prevention medication (PrEP) and addiction treatment. Sixty HIV-negative adults with op…

This completed phase 4 study looked at how to best offer cabotegravir PrEP (a long-acting injection and tablets) to Black cisgender and transgender women in the US who do not have HIV. About 370 women took part, and researchers measured how well different delivery strategies work…

This completed study looked at how to best offer cabotegravir, an HIV prevention shot, in US clinics. About 287 men and transgender men at risk for HIV took part. Researchers compared two ways of rolling out the shot to see which worked better in busy and less busy clinics.

This study tested a program where trained peer navigators (women with similar experiences) helped women in the criminal justice system access HIV prevention services like PrEP. The goal was to reduce stigma and improve linkage to care. Thirty women participated, and the study mea…

This early-stage study tested a vaginal ring that slowly releases the HIV drug tenofovir over 90 days. Researchers wanted to see if the ring is safe and delivers enough drug to the body. 49 healthy women took part, and the study measured drug levels in blood, vaginal fluid, and t…

This study tested different ways to deliver HIV testing and counseling to young men who have sex with men (ages 15-24) and their partners. The goal was to see which approach helps couples communicate better and reduce risky behaviors like condomless sex with casual partners. 71 c…

This study tested whether barbershops in the Kalangala islands of Uganda could be a good place to offer HIV prevention services to heterosexual men. Researchers enrolled 250 men and had barbers provide HIV education, hand out self-test kits, and share information about prevention…

This completed trial tested a digital program called LuvHub for male couples. The program includes modules on HIV/STI prevention, communication, and relationship goals. Over 16 months, 778 couples used the tool to create personalized prevention plans and agreements. The study mea…

This study looked at whether offering HIV prevention services, including PrEP medication, in family planning clinics helps more young women get tested for HIV and start PrEP. Over 25,000 sexually active, HIV-negative young women in Kenya took part. The goal was to see if integrat…

This pilot study tested a six-session culturally adapted cognitive behavioral therapy (Ca-CBT) for depression and anxiety in 50 people living with HIV in Pakistan. The therapy was delivered by trained HIV health workers and included culturally relevant stories and materials. The …

This study tested a new type of counseling called behavioral activation problem solving (BAPS) against standard smoking cessation counseling for people with HIV in Botswana. 651 participants were split into two groups to see which approach helped more people quit smoking. The goa…

This study tested a training program for people living with HIV to help them become more active in managing their health. The program was delivered by psychologists and aimed to improve treatment adherence, quality of life, and emotional well-being. 75 participants took part in t…

This study tested a counseling program called the Friendship Bench for 106 teens aged 13-18 who have HIV and feel depressed or anxious. The program aims to improve their mood and help them stay engaged in their HIV care. Researchers measured how well the program worked by looking…

This study looked at whether Tai Chi, a gentle mind-body exercise, can help adults over 45 living with both HIV and chronic pain. Researchers tested the program with 36 participants to see if it was practical and liked by patients. The goal was to find a non-drug way to reduce pa…

This study looked at whether medical cannabis can reduce nerve pain and inflammation in people with HIV. Thirty-five adults with HIV and neuropathic pain used different ratios of THC and CBD over 14 weeks. Researchers measured changes in pain severity and blood markers of inflamm…

This study tested whether giving HIV self-test kits to HIV-negative pregnant women for their male partners would increase the number of men who get tested for HIV. Two hundred women in Malawi were split into two groups: one where partners got a clinic referral slip, and another w…

This early-stage trial tested a single injection of JL18008, a lab-made protein designed to boost immune cells, in 40 healthy adults. The main goal was to check safety and how the body handles the drug. Researchers also measured changes in immune cell counts over 56 days. This is…

This study looked at how often thyroid problems (specifically an underactive thyroid) occur in people with HIV. Researchers reviewed medical records of 154 HIV-positive adults who were treated at a French hospital between 2001 and 2012. The goal was to get a clearer picture of th…

This study tested a more concentrated version of the long-acting HIV drug cabotegravir in 138 healthy adults. Researchers gave the injection in different ways (into muscle or under the skin) to see how the body processes it and to check for side effects. The goal was to gather sa…

This study checked whether a new HIV medicine called MK-8507 (ulonivirine) causes any changes in heart rhythm. 62 healthy adults took either the study drug, a placebo, or a control drug to compare effects. The main goal was to see if the drug safely affects the heart's electrical…

This study looked at 99 heterosexual men with HIV who are on effective antiretroviral therapy and have undetectable virus levels, comparing them to healthy men without HIV. Participants filled out questionnaires about their quality of life, depression symptoms, and sexual functio…

This study looked at how pregnancy changes the levels of the HIV drug doravirine in the blood. Seven pregnant women living with HIV took a single dose of doravirine during their second and third trimesters, and again after giving birth. The goal was to find the right dose for pre…

This study looked at whether it is possible and practical to offer rapid HIV testing to men who have sex with men (MSM) in community settings, rather than only at clinics. Researchers worked with teams in France and Canada to test this approach with 357 participants. The goal was…

This completed study looked at how regular cannabis use affects brain health and thinking skills in people with HIV and those without. Researchers used brain scans, blood and spinal fluid tests, and thinking tasks to compare 276 participants. The goal was to understand the combin…

This study looked at how many hospital patients have undiagnosed HIV. Researchers offered a rapid finger-prick HIV test to 300 patients who had certain medical conditions or behaviors that increase HIV risk. The goal was to find hidden infections and understand how common they ar…

This study follows 179 volunteers who received an experimental HIV vaccine about 10 years ago. Researchers want to see if the vaccine's immune effects and virus control have lasted. No new treatment is given; this is just an observation to gather long-term data.

This study looked at 460 people with HIV to see what types of cancer they have and why some choose to join cancer clinical trials. Researchers tracked cancers like Kaposi sarcoma, lymphoma, and HPV-related tumors. They also used surveys to learn how HIV and cancer treatments affe…

This study tested a digital, community-led program to help people in rural Appalachia and the Midwest reduce their risk of HIV and hepatitis C, often linked to opioid use. Over 500 adults took part, with half currently or previously using illicit substances. The program included …

This completed Phase 1 study tested an experimental HIV drug called VH4524184 in 126 healthy adults aged 18 to 60. The goal was to see how the drug is absorbed by the body, how it behaves when taken with food, and whether it interacts with other common medicines like metformin or…

This study looked at how a single dose of THC (the active ingredient in cannabis) changes immune-related genes and proteins in the blood. Researchers compared 56 adults with and without HIV to see if the effects differ. The goal was to understand THC's impact on the immune system…

This study looked at whether people with HIV can receive their long-acting injectable medication at general day hospitals instead of only at specialized HIV clinics. 90 patients who were already prescribed the injections were randomly assigned to one of the two settings. The main…

This study tested two different long-acting versions of the HIV drug cabotegravir in 56 healthy adults. The goal was to see how safe they are and how the body processes them. No treatment was given for HIV; the study simply gathered information to help develop better formulations…

This study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…

This study worked with 51 healthcare professionals at primary care clinics to find ways to reduce stigma toward people who use drugs, especially in HIV prevention and care. The researchers tested a program that combined education for staff and changes to clinic policies. The goal…

This completed study looked at how women who inject drugs view a long-acting injectable HIV prevention medication called CAB-LA. Researchers interviewed 144 women to understand what influences their decisions to use this option versus daily pills. The goal is to learn how to bett…

This study looked at how aging changes certain enzymes (proteins) in the blood and colon. Researchers collected blood and colon tissue samples from 21 healthy adults, both younger (18-50) and older (65-80). They also checked if the HIV medications tenofovir and emtricitabine affe…

This study followed 200 transgender and non-binary people living with HIV across Europe for 18 months. Researchers collected data from routine blood tests to see how well HIV treatment was working. The goal is to use these findings to create better treatment guidelines and design…

This study tested 350 detainees in Nîmes, France for HIV, hepatitis B, and hepatitis C using rapid diagnostic tests. Many detainees come from areas where these infections are common and often don't know their status. The goal was to find out how many are infected so that care can…

This study tested a training program for family medicine doctors in Alabama to help them talk about HIV and STI prevention with teenage girls and young women. 46 doctors took part and completed surveys before and after training to see if their knowledge and practices changed. The…

This study examined how the COVID-19 vaccine affects the immune system in people with HIV compared to those without HIV. Researchers followed 75 participants aged 55 and older for 48 weeks, taking blood and saliva samples. The goal was to understand vaccine effectiveness and any …

This study looked at how HIV and tuberculosis (TB) medications are processed in the bodies of pregnant women and their newborns. Researchers measured drug levels in blood and vaginal fluids to see if dosing needs to change during pregnancy and after birth. Over 1,500 women took p…

This study tested a method called public deliberation to improve how researchers get consent from teens for HIV prevention studies. 128 participants from diverse communities discussed ethical conflicts around parental permission versus teen self-consent. The goal was to see if th…

This study looked at how HIV and tuberculosis (TB) medications are processed in the bodies of pregnant women and new mothers. Researchers measured drug levels in the blood of 205 women during pregnancy and after delivery to see if standard doses are effective. The goal was to gat…

This study tested a program that brings in family and friends to support people receiving methadone treatment for opioid use disorder in Tanzania. The goal was to see if this social support approach is acceptable and practical, and whether it helps people stick to their methadone…

This study tested whether a single dose of pembrolizumab, a cancer drug, is safe for people with HIV who do not have cancer. The goal was to see if the drug could help reveal HIV hiding in the brain. Thirteen adults with well-controlled HIV participated. The study was not meant t…

This study followed 603 pregnant women in South Africa to see if infections or bacteria in the vagina are linked to how early they give birth. Researchers tested for sexually transmitted infections, yeast, and other germs at the start of pregnancy and again at 30-34 weeks. The go…

This study tested how acceptable HIV pre-exposure prophylaxis (PrEP) is among men who have sex with men and transgender individuals who agreed to HIV/STI testing through a community-based outreach program, both online and in person. Researchers recruited 209 participants via a ge…

This completed study in France looked at 248 people taking PrEP (a daily pill to prevent HIV) to see how their sexual behaviors and rates of other sexually transmitted infections (STIs) changed over time. Researchers compared those on PrEP for over a year to those on it for less …